Grants totaling approximately $3.5 million will support Deverra's CAR-NK and
engineered myeloid cell programs in hematologic malignancies and
solid tumors
WEXFORD,
Pa., Sept. 11, 2023 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the
Company"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, announced that Deverra Therapeutics,
Inc. ("Deverra Therapeutics") was selected by the Andy Hill CARE
Fund, Washington's Cancer Research
Endowment, for two Life Science Start-Up and Development Awards.
The recipients of the Life Science Start-up and Development awards
were announced by the CARE Fund on June
8th following a competitive peer scientific
review and selection process.
The grant funds totaling close to $3.5 million will be used to support further
pre-clinical work and product development plans for Deverra's
CAR-NK and engineered myeloid cell programs in hematologic
malignancies and solid tumors, respectively. Coeptis recently
completed an exclusive license of key assets from Deverra
Therapeutics related to its proprietary allogeneic stem cell
expansion and directed differentiation platform for the generation
of multiple distinct immune effector cell types, including natural
killer (NK) and monocyte/macrophages.
The Life Science Start-up and Development grant
was established by The Andy Hill Cancer Research Endowment (CARE)
Fund to support early-stage companies and innovative researchers to
translate promising research into the development of tools,
devices, or therapeutics related to cancer The Andy Hill CARE Fund,
signed into law in 2015 strives to leverage Washington's existing cancer research
facilities and talent to incentivize additional investment and to
advance the biotech, medical device, and health care information
technology industries in Washington. For more information about the
Andy Hill CARE Fund, click here.
"This competitive Life Science Start-Up award
from the prestigious Andy Hill CARE Fund further acknowledges the
high-level, innovative and important research that Deverra is
progressing through pre-clinical/IND-enabling and clinical trials,"
said Dave Mehalick, President and
CEO of Coeptis Therapeutics. "We congratulate the Deverra research
and management teams and are excited by the potential to build
synergies with Deverra's allogeneic, off-the-shelf NK and
macrophage (MAC) immune effector cell platform and Coeptis' target
specific CARs, which together potentially create opportunities to
develop allogeneic NK and MAC cell therapies."
About Coeptis Therapeutics Holdings,
Inc.
Coeptis Therapeutics Holdings,
Inc., together with its
subsidiaries including Coeptis Therapeutics,
Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer
that have the potential to disrupt conventional treatment paradigms
and improve patient outcomes. Coeptis' product portfolio and rights
are highlighted by assets licensed from Deverra Therapeutics,
including an allogeneic cellular immunotherapy platform and DVX201,
a clinical-stage, unmodified natural killer cell therapy
technology. Additionally, Coeptis is developing a universal,
multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the
GEAR™ cell therapy and companion diagnostic
platforms, which Coeptis is developing with VyGen-Bio and
leading medical researchers at the Karolinska Institutet.
Coeptis' business model is designed around maximizing the value of
its current product portfolio and rights through in-license
agreements, out-license agreements and co-development
relationships, as well as entering into strategic partnerships to
expand its product rights and offerings, specifically those
targeting cancer. The Company is headquartered in Wexford, PA.
For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking
Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the risk that the integration of the Deverra
licensed assets will disrupt current plans and operations of the
Company; (3) the inability to recognize the anticipated benefits of
the newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof unless required
by applicable laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics,
Inc.
Andy Galy, Sr. VP of Communications
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel
Kontoh-Boateng
dboateng@tiberend.com
Media
David
Schemelia
dschemelia@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-announces-deverra-therapeutics-has-received-two-life-science-start-up-and-development-awards-and-associated-grant-from-washingtons-cancer-research-endowment-301922777.html
SOURCE Coeptis Therapeutics